Seegene's aggregated sales surpass KRW 1 tril. this year and plans on expanding annual production capacity to KRW 5 tril. in 2021
Share: SEOUL, South Korea, Dec. 13, 2020 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnosis, Seegene Inc. (KQ096530), announced Monday that its aggregated sales this year have already surpassed the KRW 1 trillion mark, up nearly 10 times its previous annual sales of KRW 120 billion in 2019. This is largely due to an exponential surge in demand for both molecular diagnostic test kits and according PCR instruments, critical in accurately diagnosing patients. Riding on the robust growth in sales, Seegene said it plans on raising its annual production capacit...